Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 12:03 AM
Ignite Modification Date: 2025-12-25 @ 12:03 AM
NCT ID: NCT06811558
Eligibility Criteria: Inclusion Criteria: 1. Men or women aged ≥70 years; and 2. Diagnosis of plaque psoriasis ≥6 months with or without psoriatic arthritis; and 3. Plaque psoriasis involving ≥3% of body surface area (BSA) at screening and baseline,/Psoriasis Disease Area and Severity Index (PASI) score ≥3, / Static Physician Overall Score (sPGA) ≥ 2 points / DLQI \>= 6 4. the subject is suitable for biologic and/or systemic therapy for psoriasis; and 5. The purpose of the trial is well understood, and the pharmacological effects and possible adverse reactions of the test drug are well understood; the subject will be treated according to Hull's guidelines. 6. The subject has a basic understanding of the purpose of the trial, the pharmacological effects of the test drug and the possible adverse effects; and (6) The subject has voluntarily signed an informed consent form in the spirit of the Declaration of Helsinki. Exclusion Criteria: 1. With other severe skin diseases, tumors, other systemic diseases (e.g., inflammatory bowel disease), or psychiatric disorders; 2. With tuberculosis, HIV, hepatitis B, hepatitis C and other infections; 3. Those who are allergic to ezekizumab or stavudine; 4. Those who have received other systemic therapies (including but not limited to glucocorticoids, cyclosporine, methotrexate, avitamin A, azathioprine, hydroxychloroquine, thalidomide, etc.) within the previous 4 weeks; 5. Those who have participated in other clinical trials in the previous 3 months;
Healthy Volunteers: False
Sex: ALL
Minimum Age: 70 Years
Study: NCT06811558
Study Brief:
Protocol Section: NCT06811558